Hello everyone:  I’ve been on meds for six years now and have always had an
undetectable viral load in my blood, but I just recently had my semen tested
and the HIV showed up.  My doctor (about a year ago) mentioned that if this
were the case he could put me on one of the drugs (in addition to what I am
already taking) that specifically targets the viral load in the semen to get
it at an undetectable rate.  Does anyone know of this drug or the name of
it?  I’m going to contact him but I’d like to do some research on it first.

Thanks,

DRS

New Study: Drug Combo Against AIDS-Related Infections Also Prevents Malaria

ALEXANDRIA, VA — October 18, 2005 — A drug combination used to prevent
pneumonia and opportunistic bacterial infection in persons with HIV/AIDS has
unexpectedly been found to be highly effective at preventing malaria,
according to a study published in the November 15 issue of The Journal of
Infectious Diseases, now available online.

The combination, trimethoprim-sulfamethoxazole (TS), is known to reduce
morbidity and mortality from certain opportunistic infections in
HIV-infected individuals, and is widely recommended for individuals with
advanced disease, both in developed and developing countries. In addition,
TS shares many properties–including resistance patterns–with a leading
anti-malarial therapy, sulfadoxine-pyrimethamine (SP), causing concern that
widespread use of TS prophylaxis might increase the number of malarial
parasite strains resistant to SP treatment, thereby increasing the risk that
SP treatment may fail in HIV-infected individuals who contract malaria.

These concerns prompted Christopher V. Plowe, MD, MPH, and colleagues at the
University of Maryland School of Medicine and the Malaria Research and
Training Center at the University of Bamako to conduct a study to determine
whether TS prophylaxis impairs SP efficacy for treating malaria.

The investigators studied 160 children (aged 5-15 years) given TS
prophylaxis and 80 children in a control group receiving no preventive
treatment in Mali, where malaria is endemic and rates of HIV infection in
children are low. Plowe and colleagues were expecting to compare the success
of SP treatment on malarial episodes in both groups. What they encountered,
however, was just a single clinical episode of malaria in the TS group, and
the infected individual had an adequate clinical and parasitological
response to SP. In the control group, there were 72 episodes of malaria and
three instances of SP failure.

Lack of malarial episodes in the TS group precluded meaningful comparison of
SP efficacy in the TS and control groups, but, importantly, TS was shown to
be a highly effective prophylactic agent against malaria in this population,
reducing the incidence by 99.5%.

In addition to being protected against malaria, children in the TS group
also experienced fewer gastrointestinal illnesses and had slightly higher
hemoglobin levels than those in the control group. The authors pointed out
that such benefits did not mean that routine TS prophylaxis should be used
in healthy children but that they did "mitigate concerns about TS use in
HIV-exposed children whose HIV status is not yet known."

Although the authors cautioned that studies of SP efficacy in persons taking
TS prophylaxis are still needed and that SP should be used only with caution
in those taking TS who contract malaria, "based on the results of this study
and the clear evidence that TS prevents death in persons living with HIV in
a variety of African settings, concerns about spreading SP resistance do not
justify further delays in implementing TS prophylaxis."

SOURCE: Infectious Diseases Society of America

–
Gary Stein
ge.st…@verizon.net

Hey, I am just checking in to see how you two are doing!

I need to read the article that "Iconoclaster" sent to me and then get
back into the debate.

I think it’s time to pull out the heavy artillary and start learning the
basics of molecular biology.

I am in the beginning stages of understanding this whole *new language*
and need to learn it *all.*

I feel that the "final phase" of this debate (The Coup de Grace, if you
will) shall be the dissidents walking the talk right in front of the
apologits and actually learning the science, so we can shove it down their
throats.

I may even venture a little wager…

I am going to tell Chris and The Gang, that we accept their offer for a
no-holds barred debate.

We are gonna take off our gloves and battle this thing out – winner takes
all.

And I am going to tell them, when the dissidents are through, they will be
in prison for what they have done to us. Every single person who knowingly
perpetuated this lie is going to be held criminally liable for it.

We’re going to take them to court and have them prosecuted.

That is how high the stakes are now.

But first, I need to get ready! I am still going to buy my house and set
up "Dissident Central." I am going to start my own business, so that I can
have a steady income and be able to devote full-time to bringing down the
AIDS paradigm.

I am *never* giving up.

Yours truly,

-Paulee

P.S., If anyone is ready to surrender, just let us know.  We will *help
you* out of this mess!  Otherwise, we are taking you down the old
fashioned way–in a court of law.

Hey, I am just checking in to see how you two are doing!

I need to read the article that "Iconoclaster" sent to me and then get
back into the debate.

I think it’s time to pull out the heavy artillary and start learning the
basics of molecular biology.

I am in the beginning stages of understanding this whole *new language*
and need to learn it *all.*

I feel that the "final phase" of this debate (The Coup de Grace, if you
will) shall be the dissidents walking the talk right in front of the
apologits and actually learning the science, so we can shove it down
their throats.

I may even venture a little wager…

I am going to tell Chris and The Gang, that we accept their offer for a
no-holds barred debate.

We are gonna take off our gloves and battle this thing out – winner
takes all.

And I am going to tell them, when the dissidents are through, they will
be in prison for what they have done to us. Every single person who
knowingly perpetuated this lie is going to be held criminally liable for
it.

We’re going to take them to court and have them prosecuted.

That is how high the stakes are now.

But first, I need to get ready! I am still going to buy my house and set
up "Dissident Central." I am going to start my own business, so that I
can have a steady income and be able to devote full-time to bringing
down the AIDS paradigm.

I am *never* giving up.

Yours truly,

-Paulee

P.S., If anyone is ready to surrender, just let us know.  We will *help
you* out of this mess!  Otherwise, we are taking you down the old
fashioned way–in a court of law.

–
Sent via Health Newsgroups
http://www.healthnewsgroups.com

Lyme Disease Discovery Raises New Concerns About Syphilis and AIDS

http://www.anapsid.org/lyme/jones.html

this is such a simple fact, you dont need any references for that.

Janet K. Yamamoto, PhD, a professor of pathobiology at the
University of Florida College of Veterinary Medicine and member of
the board of directors of the Richard M. Brodsky Foundation has
discovered a link between the viruses that cause feline and human AIDS.

Yamamoto’s groundbreaking research may predict that cats
with feline immunodeficiency virus, also known as FIV or feline AIDS,
could possibly be more effectively treated using some form of the
experimental human vaccine. Yamamoto theorizes that the apparent
relationships between the human and feline viruses can lead to a vaccine
for human AIDS.

From Nov. 29 to Dec. 6, 2005, the foundation will be bringing
to Gainesville the World AIDS Marathon, conference, Art for AIDS
exhibition, Noor H’mara: A Concert for AIDS, nightclub awareness nights,
and H’mara: A Night of Poetry, amongst many other events, in commemoration
of World AIDS Day on Dec. 1.

Yamamoto will be speaking at the conference. She will enlighten us all
with her expertise and inspire us to strive for a cure, which may be closer than
we think.

"As an AIDS researcher and professor at the University myself, I
know that the 2005 World AIDS Marathon is a great opportunity for the
University of Florida to further enhance its research efforts in the fight against
AIDS, and I strongly urge runners and non-runners to support this very worthy
event," Yamamoto said

Yamamoto, who received a doctorate in microbiology from the University
of Texas Medical Branch in 1981, developed a vaccine for feline immunodeficiency
virus (FIV). The vaccine, called Fel-O-Vax®, was approved by the USDA in March 2002.

In 1986, Yamamoto co-discovered the deadly FIV together with Niels
Pederson, D.V.M, of the University of California at Davis.

"Just because there are medications on the market to treat HIV/AIDS, does
not mean that there is a cure," Yamamoto said. "Awareness has dropped in
the United States and it’s imperative that the public realizes that this is not a
foreign issue."

A writer for the Los Angeles times who has been covering the death of denial
Christine Maggiore’s child is now looking for input on the wider story of
HIV denialism and the damage it has done. In particular, they want to know
about any denialists who have carried their beliefs to the grave, dying of
AIDS, or more importantly people who once followed the denialist claims but
later changed their minds and pursued HIV therapy. The latter or welcome
whether or not they suffered disease progression while engaging in the
denialist beliefs.

Anyone who can help should email: Daniel Costello
Daniel.Coste…@latimes.com

It’s important that we help with stories like this. It’s crazy that we still
have to be battling with the denialists this long into the epidemic.

–
Gary Stein
ge.st…@verizon.net

http://www.dr-rath-health-foundation.org.za/rasnick_aug05.htm

| The authors state that, "Without trial evidence, this
| information must come from observational cohort studies. However,
| estimation of treatment effects in observational studies is not
| straightforward…" Indeed it is not, yet that is exactly what
| the authors did by using a "novel methodology to overcome this
| problem".
|
| To generate the results that so heartened TAC, the authors had
| to resort to a statistical method that they acknowledge "is not
| widely used in clinical research" and in fact "may not be widely
| known in the clinical research community". Yet, their results
| are not obtainable without this unused and unknown methodology.

The authors ofthe Lancet article Dr. Rasnick is criticizing used a
relatively new statistical method, "marginal structural models", to
better extract the signal of causation from the noise of confounding
factors in the observational data.

Any statistical method is mathematical by nature.  This method will
be based on assumptions about the effects a causal realationship and
confounding factors will have on the observational data, and justiified
by mathematical arguments.  There is no sign that Dr. Rasnick has
examined the assumptions and arguments supporting the new method.
Therefore, when he criticizes the new method as "unused and unknown",
he is criticizing the new method not for any known flaws, but for
the fact that he doesn’t understand it.

–
David Canzi                     "I am not denying anything." — Celia Farber

Recent study results below.
                George M. Carter

**
Nonopportunistic Neurologic Manifestations of the Human
Immunodeficiency Virus: An Indian Study
Posted 10/04/2005

Alaka K. Deshpande, MD; Mrinal M. Patnaik, MD

Abstract

Context
HIV-1 is a neurotropic virus. In a resource-limited country such as
India, large populations of affected patients now have access to
adequate chemoprophylaxis for opportunistic infections (OIs),
allowing them to live longer. Unfortunately the poor availability of
highly active antiretroviral therapy (HAART) has allowed viral
replication to proceed unchecked. This has resulted in an increase
in the debilitating neurologic manifestations directly mediated by
the virus.

Objective
The main objective of this study was to identify and describe in
detail the direct neurologic manifestations of HIV-1 in
antiretroviral treatment (ART)-naive, HIV-infected patients
(excluding the neurologic manifestations produced by opportunistic
pathogens).

Design
Three hundred successive cases of HIV-1 infected, ART-naive patients
with neurologic manifestations were studied over a 3-year period.
Each case was studied in detail to identify and then exclude
manifestations due to opportunistic pathogens. The remaining cases
were then analyzed specially in regard to their occurrence and the
degree of immune suppression (CD4+ cell counts).

Setting and Patients
The study was carried out in an apex, tertiary, referral care center
for HIV/AIDS in India. All patients were admitted for a detailed

Analysis.
No interventions were carried out, as this was an observational
study.

Results
Of the 300 cases, 67 (22.3%) had neurologic manifestations due to
the direct effects of HIV-1. The HIV infection involved the
neuroaxis at all levels. The distribution of cases showed that the
region most commonly involved was the brain (50.7%). The
manifestations included stroke syndromes (29.8%), demyelinating
illnesses (5.9%), AIDS dementia complex (5.9%), and venous sinus
thrombosis (4.4%). The other manifestations seen were peripheral
neuropathies (35.8% of cases), spinal cord pathologies (5.9% of
cases), radiculopathies (4.4% of cases), and a single case of
myopathy. The onset of occurrence of these diseases and their
progression were then correlated with the CD4+ cell counts.

Conclusions
HIV infection is responsible for a large number of nonopportunistic
neurologic manifestations that occur across a large immune spectrum.

During the early course of the disease, the polyclonal
hypergammaglobulinemia induced by the virus results in demyelinating
diseases of the central- and peripheral nervous systems (CNS and
PNS). As the HIV infection progresses, the direct toxic effects of
the virus unfold, directly damaging the CNS and PNS, resulting in
protean clinical manifestations.

Alaka K. Deshpande, MD, Professor and Head, Department of Retroviral
Medicine, Grant Medical College & Sir JJ Group of Hospitals, Mumbai,
India.

Email: alakadeshpa…@rediffmail.com.

Mrinal M. Patnaik, MD, Chief Resident, Department of Retroviral
Medicine, Grant Medical College & Sir JJ Group of Hospitals, Mumbai,
India

Disclosure: Alaka K. Deshpande, MD, has disclosed no relevant
financial relationships.

Disclosure: Mrinal M. Patnaik, MD, has disclosed no relevant
financial relationships.

Medscape General Medicine.  2005;7(3) ©2005 Medscape
http://www.medscape.com/viewarticle/511865